Searle & Co’s GSK GSK Stock Holding History

Searle & Co’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-7,224	Closed	-$278K	–	181
2024 Q2	$278K	Buy	7,224 +2,500	+53%	+$105K	0.07%	148
2024 Q1	$203K	Buy	+4,724	New	+$195K	0.05%	158
2015 Q4	–	Sell	-14,500	Closed	-$697K	–	112
2015 Q3	$697K	Buy	14,500 +13,800	+1,971%	+$718K	0.72%	46
2015 Q2	$36K	Hold	700	–	–	0.03%	193
2015 Q1	$40K	Sell	700 -3,200	-82%	-$183K	0.03%	191
2014 Q4	$208K	Buy	+3,900	New	+$218K	0.18%	106

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Searle & Co's GSK Position: Q3 2024 in Review

Searle & Co sold out of GSK (GSK) in Q3 2024, closing a stake of 7,224 shares — an estimated $278K sold.

Searle & Co first reported a position in GSK in Q4 2014 and held it in 6 quarters. The position peaked at $697K in Q3 2015. 899 funds tracked by Wall St. Rank hold GSK as of Q3 2024.

Searle & Co reported no remaining GSK position as of Q3 2024 after selling out during the quarter.
Searle & Co sold 7,224 GSK shares in Q3 2024, an estimated $278K.
Searle & Co first reported a position in GSK in Q4 2014 and held it in 6 quarters.
Searle & Co's GSK position peaked at $697K in Q3 2015.
899 funds tracked by Wall St. Rank held GSK as of Q3 2024.

Based on Searle & Co's 13F filing for Q3 2024, filed 22 Oct 2024.